LYRA
Income statement / Annual
Last year (2023), Lyra Therapeutics, Inc.'s total revenue was $1.56 M,
an increase of 14.31% from the previous year.
In 2023, Lyra Therapeutics, Inc.'s net income was -$62.68 M.
See Lyra Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
| Operating Revenue |
$1.56 M
|
$1.36 M
|
$285,000.00
|
$0.00
|
$0.00
|
$1.24 M
|
| Cost of Revenue |
$278,000.00 |
$1.07 M |
$1.00 M |
$95,000.00 |
$27,000.00 |
$0.00 |
| Gross Profit |
$1.28 M |
$296,000.00 |
-$715,999.00 |
-$95,000.00 |
-$27,000.00 |
$1.24 M |
| Gross Profit Ratio |
0.82 |
0.22 |
-2.51 |
0 |
0 |
1 |
| Research and Development
Expenses |
$47.75 M
|
$38.80 M
|
$29.69 M
|
$12.52 M
|
$12.03 M
|
$4.98 M
|
| General & Administrative
Expenses |
$19.06 M
|
$17.56 M
|
$14.21 M
|
$9.69 M
|
$4.49 M
|
$3.53 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$19.06 M
|
$17.56 M
|
$14.21 M
|
$9.69 M
|
$4.49 M
|
$3.53 M
|
| Other Expenses |
$1.59 M |
$1.32 M |
$0.00 |
$0.00 |
$0.00 |
$1.19 M |
| Operating Expenses |
$66.81 M |
$56.35 M |
$43.90 M |
$22.21 M |
$16.52 M |
$8.50 M |
| Cost And Expenses |
$67.09 M |
$56.35 M |
$43.90 M |
$22.21 M |
$16.52 M |
$8.50 M |
| Interest Income |
$4.50 M |
$1.04 M |
$102,000.00 |
$82,000.00 |
$213,000.00 |
$0.00 |
| Interest Expense |
$0.00 |
$524,000.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$278,000.00
|
$1.07 M
|
$1.00 M
|
$95,000.00
|
$27,000.00
|
$82,000.00
|
| EBITDA |
-$65.25 M
|
-$53.67 M
|
-$43.62 M
|
-$22.11 M
|
-$16.49 M
|
-$7.18 M
|
| EBITDA Ratio |
-41.88 |
-39.38 |
-153.04 |
0 |
0 |
-5.77 |
| Operating Income Ratio
|
-42.06
|
-41.31
|
-153.04
|
0
|
0
|
-5.84
|
| Total Other
Income/Expenses Net |
$2.91 M
|
$1.04 M
|
$102,000.00
|
$82,000.00
|
$213,000.00
|
$1.19 M
|
| Income Before Tax |
-$62.62 M |
-$55.27 M |
-$43.51 M |
-$22.13 M |
-$16.31 M |
-$6.03 M |
| Income Before Tax Ratio
|
-40.19
|
-40.55
|
-152.68
|
0
|
0
|
-4.85
|
| Income Tax Expense |
$59,000.00 |
$13,000.00 |
-$1.10 M |
-$82,000.00 |
-$213,000.00 |
-$1.23 M |
| Net Income |
-$62.68 M |
-$55.28 M |
-$42.41 M |
-$22.05 M |
-$16.09 M |
-$6.03 M |
| Net Income Ratio |
-40.23 |
-40.56 |
-148.81 |
0 |
0 |
-4.85 |
| EPS |
-1.26 |
-1.83 |
-3.27 |
-2.57 |
-1.25 |
-0.96 |
| EPS Diluted |
-1.26 |
-1.83 |
-3.27 |
-2.57 |
-1.25 |
-0.96 |
| Weighted Average Shares
Out |
$49.80 M
|
$30.24 M
|
$12.99 M
|
$8.59 M
|
$12.92 M
|
$6.27 M
|
| Weighted Average Shares
Out Diluted |
$49.80 M
|
$30.24 M
|
$12.99 M
|
$8.59 M
|
$12.92 M
|
$6.27 M
|
| Link |
|
|
|
|
|
|
